India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs ...

Novo Nordisk has added another dimension to its artificial intelligence ambitions by signing up as a customer of Denmark’s first so-called “supercomputer.” The supercomputer, named Gefion ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, the maker of Ozempic, as the Danish drugmaker searches for a new chief executive amid a sharp decline in its share ...

Novo Nordisk (NYSE: NVO) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

References . Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials. Symposium presentation at the American Diabetes ...

Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 By Novo Nordisk Inc. Jun 10, 2025 ...

Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) saw its stock price tick up slightly on Monday, on a media report about the possible entry of an activist investor. Market players cautiously bid ...